24-GBM-16-NL (EF-41): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant with Maintenance Temozolomide and Placebo for the Tre